MMP-8 as a novel therapeutic target in sepsis
MMP-8作为脓毒症的新治疗靶点
基本信息
- 批准号:8077606
- 负责人:
- 金额:$ 29.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcuteAdoptive TransferAdultAgeAnimalsBone MarrowCellsChildChildhoodCleaved cellClinicalClinical DataClinical ResearchCollagen Type IConditioned Culture MediaConflict (Psychology)Cytoplasmic GranulesCytoskeletonDataDevelopmentEndopeptidasesExtracellular MatrixFamilyFoundationsGene ExpressionGene Expression RegulationGene TargetingGenerationsGenesImmune systemIn VitroInflammationInflammatoryInflammatory ResponseInjuryIntraperitoneal InjectionsKnockout MiceLaboratoriesLeadLigationMeasuresMessenger RNAMetalloproteasesModelingMolecularMolecular ProfilingMusMutationNeutrophil CollagenaseOrganPathologyPatientsPatternPhenotypePlayProcessPublic HealthPuncture procedureResistanceRoleSepsisSeptic ShockSignal TransductionSourceTestingWild Type MouseWorkbasebench to bedsidecell typecollagenaseculture platesfollow-upgenome-wideimmature animalimprovedin vivoinhibitor/antagonistmacrophagemature animalmonocyteneutrophilnew therapeutic targetnovelnovel therapeuticsprogramspupresearch studyresponsetherapeutic targettissue culture
项目摘要
DESCRIPTION (provided by applicant): Septic shock is a major public health problem in both adults and children, and consequently there is a need to develop novel targets and therapeutic strategies. Based on microarray-centered clinical studies and follow up animal-centered experiments, we have indentified matrix metallopeptidase-8 (MMP-8) as a candidate target in sepsis pathology. MMP-8 is best known as a neutrophil product that cleaves collagen type 1 during extra-cellular matrix turnover. However, it has now become evident that MMP-8 also modulates acute inflammation and may play a role in sepsis pathology. The overarching hypothesis of this proposal is that MMP-8 expression and activity play a major role in sepsis pathology. We are now proposing to test this hypothesis via four complementary Specific Aims. In Specific Aim 1 we will test the hypothesis that inhibition of MMP-8 activity improves multiple endpoints relevant to sepsis pathology. This Aim will use MMP-8 null animals and a pharmacologic inhibitor of MMP-8 activity. In Specific Aim 2 we will test the hypothesis that developmental age influences the role of MMP-8 in sepsis. This Aim will use a sepsis model adaptable to 1 week old mouse pups, and will also make use of MMP-8 null mice and a pharmacologic inhibitor of MMP-8 activity. In Specific Aim 3 we will test the hypothesis that bone marrow-derived cells are the main source of MMP-8 gene regulation in sepsis. The in vivo experiments for this Aim will involve adoptive transfer of MMP-8 null bone marrow to wild-type mice, and vice versa. The in vitro experiments for this Aim will systematically elucidate the signaling mechanisms that lead to de novo MMP-8 gene expression in neutrophils and monocytes. In Specific Aim 4 we will test the hypothesis that collagen type 1 degradation products are involved in the mechanism by which MMP-8 regulates inflammation. The in vitro experiments for this Aim will test the ability of conditioned media, derived from collagen type 1 coated tissue culture plates treated with activated MMP-8, to activate macrophages. The in vivo experiments for this Aim will measure the response to sepsis in mice having a mutation of collagen type 1, which renders it resistant to cleavage by MMP-8. The major deliverables of this proposal include the establishment of MMP-8 as a novel therapeutic target in sepsis, the elucidation of how development influences the role of MMP-8 in sepsis, the elucidation of the major cellular source of MMP-8 in sepsis, a comprehensive understanding of the signaling mechanisms involved in MMP-8 expression during inflammation, and the establishment of MMP-8-dependent collagen type 1 degradation products as danger associated molecular patterns for the innate immune system.
PUBLIC HEALTH RELEVANCE: The deliverable of this program will be the elucidation of a major role for MMP-8 expression and activity in sepsis pathology. Public health will be positively impacted by providing the foundation for the development of a novel therapeutic strategy for clinical sepsis.
描述(由申请人提供):感染性休克是成人和儿童的主要公共卫生问题,因此需要开发新的靶点和治疗策略。基于以芯片为中心的临床研究和以动物为中心的后续实验,我们已经确定基质金属肽酶-8(MMP-8)作为脓毒症病理学的候选靶点。MMP-8最为人所知的是在细胞外基质周转期间切割1型胶原蛋白的嗜中性粒细胞产物。然而,现在已经变得明显的是,MMP-8也调节急性炎症,并可能在脓毒症病理学中发挥作用。该建议的总体假设是MMP-8的表达和活性在脓毒症病理学中起主要作用。我们现在建议通过四个互补的具体目标来检验这一假设。在具体目标1中,我们将检验抑制MMP-8活性改善与脓毒症病理学相关的多个终点的假设。该目的将使用MMP-8无效动物和MMP-8活性的药理学抑制剂。在具体目标2中,我们将检验发育年龄影响MMP-8在脓毒症中的作用的假设。该目的将使用适合于1周龄小鼠幼仔的脓毒症模型,并且还将使用MMP-8缺失小鼠和MMP-8活性的药理学抑制剂。在具体目标3中,我们将检验骨髓源性细胞是脓毒症中MMP-8基因调控的主要来源这一假设。用于该目的的体内实验将涉及MMP-8缺失骨髓向野生型小鼠的过继转移,反之亦然。为此目的的体外实验将系统地阐明导致中性粒细胞和单核细胞中MMP-8基因重新表达的信号传导机制。在具体目标4中,我们将检验1型胶原降解产物参与MMP-8调节炎症的机制的假设。为此目的的体外实验将测试条件培养基激活巨噬细胞的能力,所述条件培养基来源于用活化的MMP-8处理的1型胶原包被的组织培养板。用于该目的的体内实验将测量具有1型胶原突变的小鼠中对脓毒症的反应,所述1型胶原突变使其对MMP-8的切割具有抗性。该提案的主要成果包括确立MMP-8作为脓毒症的新治疗靶点,阐明发展如何影响MMP-8在脓毒症中的作用,阐明MMP-8在脓毒症中的主要细胞来源,全面了解炎症期间MMP-8表达的信号传导机制,以及MMP-8依赖性1型胶原降解产物作为先天免疫系统的危险相关分子模式的建立。
公共卫生相关性:该项目的成果将是阐明MMP-8的表达和活性在脓毒症病理学中的主要作用。通过为临床脓毒症的新治疗策略的开发提供基础,将对公共卫生产生积极影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HECTOR R. WONG其他文献
HECTOR R. WONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HECTOR R. WONG', 18)}}的其他基金
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
- 批准号:
8841381 - 财政年份:2014
- 资助金额:
$ 29.05万 - 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
- 批准号:
9234036 - 财政年份:2014
- 资助金额:
$ 29.05万 - 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
- 批准号:
8695557 - 财政年份:2014
- 资助金额:
$ 29.05万 - 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
- 批准号:
8970115 - 财政年份:2014
- 资助金额:
$ 29.05万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 29.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 29.05万 - 项目类别:
Operating Grants